VaxInnate to Present at Cantor Fitzgerald's Inaugural Healthcare Conference
01. Juli 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, July 1, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology, today announced plans to present a company overview at Cantor...
VaxInnate Appoints Former CDC Division Chief Thomas Monath to Board of Directors
17. Juni 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, June 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the appointment of Thomas P. Monath,...
VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, into Phase 2 Study
03. Juni 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, June 3, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, today announced the
initiation of a double-blind,...
VaxInnate Enhances R&D Program and Strengthens Senior Management Team to Drive Pipeline Development of Current and Potential Targets
13. Mai 2015 08:00 ET
|
Scienta Communications
Cranbury, NJ, May 13, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced two strategic
promotions and two additions to...
VaxInnate to Present at Needham & Company 14th Annual Healthcare Conference
07. April 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, April 7, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced plans to present
at the Needham & Company 14th...
VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines
17. Februar 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Feb. 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced that it has
executed a contract modification...
VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly
08. Dezember 2014 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Dec. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, today announced the
initiation of a double-blind,...
VaxInnate Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints
11. November 2014 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Nov. 11, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering
next-generation vaccine technology, announced today that enrollment
has concluded in the Phase 1...
VaxInnate Updates Plans to Advance Lead Vaccine Candidate, VAX2012Q in Elderly
08. Oktober 2014 09:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Oct. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, provided an update on
clinical development plans for...